Brief: Adc Therapeutics Announces Completion Of Enrollment Of Phase 3 Confirmatory Clinical Trial Of Zynlonta In Combination With Rituximab In 2L+ Diffuse Large B-Cell Lymphoma
30/12/2024 21:51
Dec 30 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT OF
PHASE 3
CONFIRMATORY CLINICAL TRIAL OF ZYNLONTA® IN COMBINATION WITH
RITUXIMAB IN 2L+ DIFFUSE LARGE B-CELL LYMPHOMA
Source text: ID:nPn4FzrXCa
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ADC Therapeutics SA
See all newsADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million